Observational study on efficacy and safety of vaccines against the novel coronavirus disease (COVID-19) in hematopoietic stem cell transplantation (HSCT) patient.
Not Applicable
Recruiting
- Conditions
- allo-SCT
- Registration Number
- JPRN-UMIN000043671
- Lead Sponsor
- Fukuoka Blood and Marrow Transplantation Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
1.Grade III-IV acute GVHD at the time of registration. 2.Anti-CD20 antibody therapy within 6 months. 3.CAR-T cell therapy within 6 months with B cell depletion. 4.Anti-thymocyte globulin (ATG) or alemtuzumab therapy within 6 months. 5.Judged to be inappropriate by the principal investigator and the research coordinator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluations of COVID-19 antibody titers before and after vaccination.
- Secondary Outcome Measures
Name Time Method